Metabolic Health Risks to Consider for Obesity & Diabetes

Explore the connections among obesity, diabetes, and metabolic health to make better lifestyle choices and improve well-being.

Abstract

In this educational post, I present a clear, evidence-based journey through how obesity intersects with type 2 diabetes and cardiovascular disease, why chronic inflammation and neuroendocrine dysregulation sit at the center of these conditions, and how modern therapies—including GLP-1/GIP agonists, SGLT2 inhibitors, and targeted lifestyle strategies—modulate the underlying physiology. You will see how we apply modern research methods—continuous glucose monitoring (CGM), cardiometabolic risk stratification, noninvasive assessment of liver fibrosis, guideline-directed pharmacotherapy, and integrative chiropractic and rehabilitation—to personalize treatment. I explain why obesity is a chronic, relapsing, treatable disease and how metabolic adaptation drives weight regain without long-term, biology-targeted care. I also describe how our multidisciplinary model at Injury Medical Clinic PA (Mission Plaza Injury Medical Clinic) in El Paso, Texas integrates chiropractic care, functional medicine, personal injury rehabilitation, and medical oversight. Our team is led clinically by me, Dr. Alex Jimenez, DC, APRN, FNP-BC, CFMP, IFMCP, ATN, CCST, alongside Dr. Maria Guadalupe Cardenas, MD (Board Certified in Internal Medicine; NPI #1164426749; Texas MD License #J2933), who serves as our Medical Director and Collaborative Physician. Two detailed case narratives demonstrate stepwise reasoning, physiologic underpinnings, and practical protocols. We conclude with key takeaways linking obesity treatment to improved glycemic control and reduced cardiometabolic risk, supported by recent consensus and guideline statements.

My Role and Our Multidisciplinary Team-Based Model in El Paso, Texas

As a clinician with a passion for functional and integrative medicine, I am Dr. Alex Jimenez. With credentials including DC, APRN, FNP-BC, CFMP, IFMCP, ATN, and CCST, my focus has always been on understanding the root cause of complex chronic conditions. Today, I want to share some pivotal insights into a topic that affects millions: the intricate relationship between obesity, diabetes, and cardiometabolic health.

I practice at Injury Medical Clinic PA, also known as Mission Plaza Injury Medical Clinic, in El Paso, Texas. Our clinic reflects the modern, integrative model common in functional and injury care—where chiropractic care, internal medicine, and rehabilitation collaborate in a single, unified plan. I provide integrative chiropractic and functional medicine services, while Dr. Maria Guadalupe Cardenas, MD, a board-certified internist with over 40 years of experience (NPI #1164426749; Texas MD License #J2933), is our Medical Director and Collaborative Physician. Her extensive medical knowledge provides essential oversight and complements our integrative care model.

• What I do:

• • Provide comprehensive biomechanical assessment and integrative chiropractic care to reduce nociceptive drive, improve joint mechanics, and normalize movement patterns.
  • Apply functional medicine diagnostics to map metabolic, endocrine, and inflammatory contributors to obesity, type 2 diabetes, and cardiometabolic risk.
  • Coordinate rehabilitation, neuromuscular re-education, and lifestyle therapeutics.
  • Assess hormonal transitions (e.g., menopause), sleep, stress, circadian rhythm, nutrition quality, and environmental drivers. We leverage biomarkers and validated tools (CGM, HOMA-IR, FIB-4).

• What Dr. Cardenas does:

• • Offers medical oversight, ensuring safety, care coordination, and adherence to internal medicine standards.
  • Manages pharmacotherapy (e.g., GLP-1 receptor agonists, dual GLP-1/GIP agonists, SGLT2 inhibitors, antihypertensives, lipid-lowering regimens).
  • Guides decisions on comorbidity screening, labs, and diagnostics, and monitors cardiometabolic outcomes over time.

• How we integrate:

• • Shared care plans align chiropractic and rehab interventions with medical therapy and functional nutrition.
  • Continuous monitoring of inflammatory markers, lipid profiles, glucose metrics, and blood pressure informs titration of therapies.
  • Regular case conferences align manual therapy intensity with glycemic trends, antihypertensive adjustments, and patient-reported outcomes.

This team-based model allows us to target the same physiological core with complementary tools, producing more reliable outcomes than siloed approaches.

Understanding Obesity as a Chronic, Relapsing, Treatable Disease

From an integrative perspective, I frame obesity as a condition of neuroendocrine dysregulation, chronic inflammation, and impaired energy homeostasis—not a simple calorie imbalance. The body’s weight set point is tightly regulated by hypothalamic circuits that interpret signals from adipose tissue, the gut, and the immune system. When these circuits become dysregulated, the biology of hunger and satiety changes.

• Core physiology:

• • Leptin resistance: Adipose tissue secretes leptin to signal satiety and adequate energy stores, but hypothalamic inflammation can blunt leptin signaling. The brain “perceives” starvation despite excess energy stores, prompting compensatory hunger and reduced energy expenditure (Schwartz et al., 2017).
  • Ghrelin elevation and satiety hormone decline: Dysregulated ghrelin and impaired PYY/GLP-1 signaling increase hunger and decrease fullness, promoting higher intake (Müller et al., 2015).
  • Hypothalamic inflammation: Microglial activation and cytokine signaling in the arcuate nucleus disrupt melanocortin pathways (POMC/CART and NPY/AgRP neurons), shifting the defended fat mass upward (Thaler et al., 2013).
  • Metabolic adaptation: Weight loss triggers a persistent drop in resting energy expenditure that exceeds the predicted effect of mass changes, alongside increased hunger—physiological brakes that drive weight regain (Doucet & Cameron, 2007).

• Clinical insight I share with patients:

• • Overeating is often a downstream effect of dysregulated biology. In other words: “Overeating does not cause obesity; obesity causes overeating” in many individuals once neuroendocrine dysregulation is established.
  • This is why medication that targets biologic drivers, integrated with rehabilitation and lifestyle strategies, is justified early—similar to how we treat type 2 diabetes.

The Intersection: Obesity, Type 2 Diabetes, and Cardiovascular Disease

These conditions share common pathophysiological threads: chronic inflammation, insulin resistance, oxidative stress, endothelial dysfunction, and mitochondrial impairment. The American Diabetes Association (ADA) emphasizes that diabetes management must address glycemia, weight, and cardiometabolic risk, including cardiovascular, liver, and kidney disease risk factors. Treating obesity improves all of these targets by reducing insulin resistance, lowering inflammatory cytokines, improving lipid profiles, and reducing ectopic fat in the liver and viscera (American Diabetes Association, 2025; Davies et al., 2023).

• Obesity to diabetes:

• • Ectopic fat deposition and lipotoxicity impair insulin signaling in liver and muscle, increasing hepatic glucose output and reducing peripheral glucose uptake (Samuel & Shulman, 2016).
  • Over time, beta-cell stress and glucotoxicity contribute to declining insulin secretion, progressing from insulin resistance to prediabetes and diabetes (Kahn et al., 2014).

• Obesity/diabetes to cardiovascular disease:

• • Atherosclerosis is fueled by vascular inflammation, LDL infiltration and oxidation, and maladaptive immune responses within the intima (Libby et al., 2019).
  • Endothelial nitric oxide (NO) bioavailability falls with oxidative stress and inflammatory cytokines, promoting vasoconstriction, platelet aggregation, and endothelial dysfunction, while reducing insulin-mediated vasodilation and glucose disposal (Muniyappa & Sowers, 2013).

• The NO link:

• • Adequate NO supports mitochondrial efficiency and insulin sensitivity. Loss of NO contributes to increased triglyceride levels, decreased glucose tolerance, and increased oxidative stress—bridging metabolic and vascular dysfunction (Tang et al., 2014).

This is why interventions that reduce inflammation and improve NO signaling can favorably shift both metabolic and cardiovascular trajectories.

Setting Realistic and Effective Weight Loss Goals

It’s essential to educate patients on how much weight loss is needed to see meaningful health improvements. It’s often less than people think to start seeing benefits, but more is needed for full disease remission.

• ≥5% weight loss: improvements in A1C by ~0.2–0.3%, triglycerides, and blood pressure.
• ≥10% weight loss: often required for significant improvement or potential remission of prediabetes.
• ≥10–15% weight loss: larger A1C reductions (~1%), medication de-escalation in diabetes and hypertension, improved HDL/LDL profiles, and enhanced quality of life (Rubino et al., 2016; Wilding et al., 2021). For established conditions like Type 2 Diabetes, Hypertension, Dyslipidemia, and NAFLD (Non-alcoholic fatty liver disease), a 15% or greater weight loss is typically needed to achieve substantial improvement or remission.

This data is crucial for setting expectations and choosing the right treatment modality. It helps patients understand that while a 5-pound weight loss is a great start, achieving their ultimate health goals may require a more intensive approach.

The Four Pillars of Treatment

My approach is built on the four pillars of obesity treatment: nutrition, physical activity, behavioral health, and medical management.

1. Nutrition Strategy: The best nutritional plan is one that the patient enjoys and can sustain over the long term. We focus on a caloric deficit, reducing simple carbs while increasing lean protein and fiber, and often refer to a Registered Dietitian for personalized medical nutrition therapy.
2. Behavioral Health Support: We assess for stress, anxiety, depression, and sleep issues. When needed, we refer patients to behavioral health specialists for cognitive-behavioral therapy (CBT) for obesity, which helps change thought patterns that contribute to weight gain.
3. Physical Activity Plan: Movement is medicine. We recommend 150–300 minutes of moderate-intensity aerobic activity, a step goal of 5,000–10,000 steps per day, and at least two days of resistance training per week to build muscle and boost metabolic rate.
4. Medical Management: For many patients, lifestyle changes alone are not enough to overcome the powerful biology of obesity. This is where medical management becomes a critical fourth pillar.

---

Chiropractic Care & Metabolism *The Hidden Link*- Video

---

Modern Pharmacotherapies: Where They Work and Why We Use Them

I collaborate with Dr. Cardenas to select and monitor medications that target the pathophysiology while integrating manual therapy and rehab.

• FDA-approved anti-obesity agents:

• • GLP-1 receptor agonists (liraglutide, semaglutide): Enhance satiety, slow gastric emptying, reduce energy intake, and improve glycemic control; beneficial effects on inflammation and endothelial function are under investigation. Semaglutide has demonstrated double-digit weight loss and cardiometabolic benefits (Wilding et al., 2021; SELECT Investigators, 2023).
  • Dual GLP-1/GIP agonist (tirzepatide): Synergistically augments incretin signaling, leading to higher weight loss and potent glycemic effects; favorable impacts on lipids and blood pressure have been observed (Jastreboff et al., 2022).
  • Naltrexone/bupropion SR: Targets reward and appetite pathways in the hypothalamus; useful for patients with hedonic eating patterns (Greenway et al., 2010).
  • Phentermine/topiramate ER: Combines sympathomimetic appetite suppression with enhanced satiety; requires monitoring for cardiovascular and cognitive side effects (Gadde et al., 2011).
  • Orlistat: Inhibits fat absorption; leads to modest weight loss with gastrointestinal side effects; may suit patients unable to use central agents.

• Diabetes medications with weight and cardiac benefits:

• • SGLT2 inhibitors: Lower glucose via urinary excretion, reduce weight modestly, and provide robust heart failure and renal protection (Zinman et al., 2015).
  • GLP-1 RAs: Reduce major adverse cardiovascular events in high-risk patients (Marso et al., 2016; SELECT Investigators, 2023).

• Why early combination makes sense:

• • Diabetes care layers medications to target multiple defects. In obesity, formal guidelines lag, but clinical practice often judiciously combines agents. We align pharmacology with functional medicine strategies to improve sleep, stress physiology, nutrient timing, and activity—all factors that modulate hypothalamic inflammation and insulin resistance.

• Avoiding obesogenic medications when possible:

• • We review medications for weight-promoting effects (e.g., sulfonylureas, TZDs, insulin, certain beta-blockers). Where clinically safe, Dr. Cardenas and I substitute weight-neutral or weight-reducing options to increase the probability of achieving A1C targets and sustaining weight loss.

The Physiology of Weight Regain and Why Long-Term Treatment Matters

Patients often tell me they can lose weight but it “finds five friends and returns.” That is not a willpower failure; it’s metabolic adaptation.

• What happens after weight loss:

• • Resting energy expenditure drops and remains suppressed for months to years.
  • Ghrelin rises, and satiety hormones fall, increasing hunger.
  • The hypothalamus “defends” the higher fat mass, driving regain (Doucet & Cameron, 2007).

• Clinical evidence:

• • After discontinuing semaglutide, participants in STEP-extension analyses rapidly regained weight and saw reversals in cardiometabolic improvements, including rises in blood pressure and A1C—even among those not previously hypertensive or diabetic (Wilding et al., 2021; Rubino et al., 2021).

• My practice approach:

• • I frame obesity as a lifelong, medically managed condition. We plan for sustained care—adjusting medications, renewing rehab phases, and maintaining chiropractic and functional support to protect the musculoskeletal system as body composition changes.

Case Studies in Integrated Care

To illustrate our clinical approach, let me introduce you to two patients who represent common challenges we see.

Case 1: A Young Man with Prediabetes and Obesity

“Stephen,” a 24-year-old male, came to our clinic for help with weight management after a prediabetes diagnosis.

• Initial Presentation: Stephen’s hemoglobin A1c was 5.8%, indicating prediabetes. Despite trying to change his diet, his weight continued to climb. His family history was significant for obesity, cardiovascular disease, and type 2 diabetes. His weight gain began around age 13, coinciding with the stress of his parents’ divorce—a crucial link between stress, cortisol, and weight gain.
• Assessment: At 250 pounds, his BMI was 32.1 (Class 1 Obesity). His exam revealed a 41-inch waist circumference, a 17-inch neck circumference (a risk factor for sleep apnea), and acanthosis nigricans—a visible sign of high insulin levels.
• Treatment Plan: I asked Stephen: “Would you be interested in a treatment that would not only help you lose weight but also prevent you from developing diabetes?” His enthusiastic “Absolutely yes!” was our starting point. We discussed the four pillars of treatment and the power of modern medications. After reviewing the options, Stephen elected to start tirzepatide, a dual GIP/GLP-1 agonist.
• The SURMOUNT-1 Trial: A key piece of evidence I shared was from the SURMOUNT-1 trial (Jastreboff et al., 2022). This landmark study found that 99% of prediabetic participants treated with tirzepatide remained free of diabetes, and those on the highest dose achieved an average weight reduction of nearly 23%. This data powerfully illustrates the potential of proactive medical management.
• Progress: We started tirzepatide at a low dose and set manageable lifestyle goals. Frequent follow-ups (every 2-4 weeks initially) were key to adjusting the plan and maintaining momentum. One year later, Stephen had lost 50 pounds (a 20% total body weight loss), his BMI dropped to 25.7, and his A1c was 5.4%, placing his prediabetes in remission.

Case 2: A Woman Navigating Menopause, Diabetes, and Weight Gain

I met Victoria, a 52-year-old woman, for follow-up of prediabetes that had progressed to diabetes alongside recent weight gain.

• Initial Clinical Picture: Victoria was postmenopausal, with a 15-pound weight gain over the past year. Her labs revealed a new diagnosis of diabetes (A1C 7.3%) and significant insulin resistance (HOMA-IR 4.7). She also had sleep disruption with night sweats, a common symptom of menopause.
• Physiologic Context: Menopause and Metabolic Risk: The menopause transition involves a decline in estradiol, which commonly leads to increases in LDL-C, insulin resistance, sleep disruption, and a shift in fat deposition to the abdomen. These changes significantly elevate cardiovascular risk (Manson et al., 2023; El Khoudary et al., 2020).
• Integrated Plan: Working with Dr. Cardenas, we created a plan that included increasing her metformin dose, starting a 14-day trial of Continuous Glucose Monitoring (CGM) to uncover glycemic patterns, and a referral to a menopause specialist to evaluate her for Menopausal Hormone Therapy (MHT).
• Adding GLP-1 RA: After one month, Victoria had started MHT, which helped with her hot flashes. We then added semaglutide, a GLP-1 receptor agonist, to her regimen. The rationale was to enhance satiety, promote weight loss, and leverage its known cardioprotective benefits (Wilding et al., 2021; Marso et al., 2016).
• One-Year Outcomes: Victoria’s weight decreased from 185 lbs to 160 lbs, her A1C improved significantly, and her lipid levels trended favorably. Treating her obesity directly enhanced her diabetes control and lowered her overall cardiometabolic risk.

Integrative Chiropractic Care: Where It Fits and Why It Improves Outcomes

As weight and metabolic status change, the musculoskeletal system must adapt. Pain, joint stiffness, and poor movement patterns can block progress on activity goals. This is where integrative chiropractic care is uniquely valuable.

• Mechanisms and clinical rationale:

• • Spinal and extremity adjustments: Normalize segmental motion, reduce nociceptive input, and improve sensorimotor integration. Reduced nociception reduces sympathetic overdrive, which can improve sleep quality and stress physiology, thereby supporting appetite regulation and glucose control.
  • Soft-tissue and myofascial therapies: Decrease local inflammatory mediators and improve tissue glide, enabling more efficient movement with reduced pain.
  • Movement retraining and rehab: Corrective exercise enhances joint centration, load distribution, and muscle coordination. Better biomechanics enable safer, more frequent activity—thereby supporting mitochondrial fitness and insulin sensitivity.
  • Postural and gait optimization: With weight reduction, center-of-mass shifts. Strategic retraining prevents compensatory strain, protecting knees/hips/spine and helping patients sustain activity adherence.
  • Breathing mechanics and rib mobility: Diaphragmatic training can favorably affect autonomic balance and NO generation in the airway, complementing vascular NO pathways.

• Clinical observations in my practice:
  • When patients experience even modest pain reductions, they are more likely to achieve activity targets. This translates into reduced glycemic variability, improved blood pressure, and a positive feedback loop in which movement becomes self-reinforcing.
  • My documented case insights and thought leadership, which I share through my professional channels and clinic website, consistently highlight that coupling manual therapy with targeted exercise creates a practical path for patients who previously “could not move without pain” to engage in the very activities that drive metabolic improvement. See clinical observations and educational insights at:

• • • https://dralexjimenez.com/
    • https://www.linkedin.com/in/dralexjimenez/

In Victoria’s case, chiropractic care was crucial. I addressed cervical-thoracic junction stiffness that contributed to her sleep discomfort and implemented lumbopelvic stability work, enabling her to engage in progressive resistance training with less soreness.

Functional Medicine Lens: Personalizing the Plan

Functional medicine helps us map upstream contributors to obesity and cardiometabolic disease:

• Endocrine disruptors and medications: Some agents can be obesogenic; medication reconciliation and minimizing environmental exposures are part of our plan.
• Microbiome and dysbiosis: We prioritize fiber, fermented foods as tolerated, and diverse plant intake to improve SCFA production and gut barrier function, thereby modulating inflammation and appetite signals (Cani & Everard, 2015).
• Micronutrients: We assess and address vitamin D, magnesium, and omega-3 status, given their roles in insulin signaling, vascular function, and inflammation.
• Chrononutrition: Timing and distribution of protein and fiber help regulate appetite hormones and glycemic control. For selected patients, time-restricted eating is considered, with safeguards to prevent hypoglycemia and account for medication timing.

By tailoring interventions to each patient’s physiology and constraints, we increase adherence and durability.

Closing Perspective: Treat the Biology, Support the Body, Sustain the Wins

When we treat obesity as the disease it is—chronic, progressive, relapsing, and treatable—we unlock better outcomes for diabetes and cardiovascular disease. We combine medical oversight from Dr. Maria Guadalupe Cardenas, MD, with integrative chiropractic care, rehabilitation, and functional medicine to address root physiology and help the musculoskeletal system support sustained activity and resilience.

In practical terms, that means:

• Target the hypothalamus and inflammatory pathways with modern pharmacology and a precise lifestyle.
• Restore and protect movement with chiropractic care and rehab, reducing pain barriers and improving adherence.
• Maintain gains with long-term strategies that respect metabolic adaptation.

This is the future—and the present—of cardiometabolic care in a multidisciplinary clinic.

References

• American Diabetes Association. (2025). Standards of Care in Diabetes—2025. Diabetes Care.
• Apovian, C. M., Aronne, L., & Bessesen, D. H. (2013). Pharmacological management of obesity: an Endocrine Society clinical practice guideline. JAMA.
• Beck, R. W., Riddlesworth, T., Ruedy, K., et al. (2019). Effect of continuous glucose monitoring on glycemic control in adults with type 2 diabetes using basal insulin or no insulin. New England Journal of Medicine.
• Cani, P. D., & Everard, A. (2015). Talking microbes: When gut bacteria interact with diet and host organs. Molecular Nutrition & Food Research, 59(1), 7–14.
• Davies, M. J., et al. (2018). Management of hyperglycemia in type 2 diabetes, 2018: A consensus report by the ADA and EASD. Diabetes Care, 41(12), 2669–2701.
• Davies, M., Færch, K., Jeppesen, O. K., et al. (2023). Semaglutide and weight management in type 2 diabetes. International Journal of Obesity.
• Doucet, E., & Cameron, J. (2007). Appetite control after weight loss: What is the role of body fat? Appetite, 49(3), 691–697.
• (2024). EASL Clinical Practice Guidelines on MASLD. Journal of Hepatology.
• El Khoudary, S. R., et al. (2020). Menopause transition and cardiovascular disease risk. Circulation.
• Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. E., et al. (2023). Resmetirom for the treatment of NASH with liver fibrosis. New England Journal of Medicine.
• Gadde, K. M., et al. (2011). Effects of low-dose, controlled-release, phentermine plus topiramate on weight and associated comorbidities in overweight and obese adults. Lancet, 377(9774), 1341–1352.
• Greenway, F. L., et al. (2010). Naltrexone/bupropion for weight management: Efficacy and safety in a phase 3 trial. Obesity, 18(12), 2339–2347.
• Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177–185.
• Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
• Kahn, S. E., Cooper, M. E., & Del Prato, S. (2014). Pathophysiology and treatment of type 2 diabetes. Lancet, 383(9922), 1068–1083.
• Libby, P., Buring, J. E., Badimon, L., et al. (2019). Atherosclerosis. Nature Reviews Disease Primers, 5(1), 56.
• Look AHEAD Research Group. (2013). Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine, 369(2), 145–154.
• Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2023). Menopausal hormone therapy and health outcomes. Circulation.
• Marso, S. P., Daniels, G. H., Brown-Frandsen, K., et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine, 375(4), 311- 322.
• Müller, T. D., et al. (2015). Ghrelin. Molecular Metabolism, 4(6), 437–460.
• Muniyappa, R., & Sowers, J. R. (2013). Role of insulin resistance in endothelial dysfunction. Reviews in Endocrine and Metabolic Disorders, 14(1), 5–12.
• Roden, M., & Shulman, G. I. (2019). The integrative biology of type 2 diabetes. Nature, 576(7785), 51–60.
• Rubino, D. M., et al. (2021). Weight regain and cardiometabolic effects after withdrawal of semaglutide: STEP 4 extension. Diabetes, Obesity and Metabolism, 23(9), 1995–2005.
• Rubino, F., et al. (2016). Metabolic surgery in the treatment algorithm for type 2 diabetes. Diabetes Care, 39(6), 861–877.
• Samuel, V. T., & Shulman, G. I. (2016). The pathogenesis of insulin resistance. Cell, 148(5), 852–871.
• Schwartz, M. W., et al. (2017). Obesity pathogenesis: an endocrine society scientific statement. Endocrine Reviews, 38(4), 267–296.
• SELECT Investigators. (2023). Semaglutide and cardiovascular outcomes in overweight or obese patients with cardiovascular disease. New England Journal of Medicine, 389, 2221–2232.
• Tang, X., et al. (2014). Nitric oxide and insulin resistance. American Journal of Physiology-Endocrinology and Metabolism, 307(10), E918–E925.
• Thaler, J. P., et al. (2013). Obesity is associated with hypothalamic injury in rodents and humans. Journal of Clinical Investigation, 122(1), 153–162.
• Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
• Zinman, B., et al. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine, 373(22), 2117–2128.

SEO tags: integrative chiropractic care, obesity treatment, cardiometabolic health, GLP-1 semaglutide, tirzepatide, SGLT2 inhibitors, nitric oxide endothelial function, hypothalamic inflammation, functional medicine obesity, El Paso chiropractic clinic, Injury Medical Clinic PA, Mission Plaza Injury Medical Clinic, Dr. Alex Jimenez, Dr. Maria Guadalupe Cardenas, weight regain metabolic adaptation, atherosclerosis inflammation, rehabilitation for obesity, movement therapy diabetes, internal medicine collaborative care, Prediabetes Treatment, SURMOUNT-1 Trial, Insulin Resistance, A1c, Multidisciplinary Clinic, Metabolic Health, Bariatric Surgery Alternatives, GLP-1 Agonists, Personalized Medicine, Chronic Disease Management, Lifestyle Intervention, diabetes management, menopause hormone therapy, CGM benefits, MASLD fibrosis FIB-4, resmetirom NASH, cardiometabolic risk reduction, rehabilitation and weight loss, evidence-based obesity care